Physician profile
Emma Martz
NPI 1780178723
$1,901.70
in general payments reported to CMS, 2019-2025
29 companies · $670 in 2025
The $670 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.20 · 2020: $18.72 · 2021: $176 · 2022: $365 · 2023: $337 · 2024: $283 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,290.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $259.35 | 2021-2025 | |
| Novo Nordisk INC | $184.01 | 2021-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.52 | 2021-2025 | Jardiance, Tradjenta, Trijardy Xr |
| Astrazeneca Pharmaceuticals LP | $138.22 | 2019-2024 | Breztri |
| Amgen INC. | $130.97 | 2022-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $117.74 | 2021-2025 | |
| Lilly USA, LLC | $113.87 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $73.91 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Gilead Sciences, INC. | $72.91 | 2022 | |
| Lundbeck LLC | $67.07 | 2023-2025 | Rexulti, Brintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.33 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $66.08 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $62.19 | 2024-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $40.92 | 2021 | |
| Alkermes, INC. | $38.70 | 2022-2025 | Lybalvi |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $36.89 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $35.18 | 2023-2025 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $34.51 | 2023-2024 | |
| Ardelyx, INC. | $31.03 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $29.24 | 2024 | Voquezna |
| Ibsa Pharma INC. | $20.56 | 2025 | Flector, Licart, Tirosint |
| Vanda Pharmaceuticals INC. | $19.89 | 2025 | Hetlioz, Fanapt |
| Tris Pharma INC | $19.19 | 2025 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $18.72 | 2020 | |
| Neurocrine Biosciences, INC. | $17.57 | 2024 | Ingrezza |
| Medtronic, INC. | $16.34 | 2023 | Minimed 780g |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.75 | 2025 | Xifaxan |
| Dexcom, INC. | $13.84 | 2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Martz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.